Adagene to Present at Jefferies Global Healthcare Conference 2025
Adagene Inc. (Nasdaq: ADAG), a biotechnology company focused on antibody-based therapies, announced its participation in the Jefferies Global Healthcare Conference 2025. Chief Strategy Officer Mickael Chane-Du will engage in one-on-one investor meetings and participate in a fireside chat on June 5, 2025, from 9:20-9:50 AM ET at the New York Marriott Marquis. The presentation will be available via webcast and accessible through the company's investor relations website for a minimum of 30 days.
Adagene Inc. (Nasdaq: ADAG), un'azienda biotecnologica specializzata in terapie a base di anticorpi, ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference 2025. Il Chief Strategy Officer Mickael Chane-Du terrà incontri individuali con investitori e parteciperà a una tavola rotonda il 5 giugno 2025, dalle 9:20 alle 9:50 AM ET presso il New York Marriott Marquis. La presentazione sarà disponibile in webcast e accessibile tramite il sito web delle relazioni con gli investitori dell'azienda per almeno 30 giorni.
Adagene Inc. (Nasdaq: ADAG), una empresa biotecnológica centrada en terapias basadas en anticuerpos, anunció su participación en la Jefferies Global Healthcare Conference 2025. El Director de Estrategia, Mickael Chane-Du, mantendrá reuniones individuales con inversores y participará en una charla informal el 5 de junio de 2025, de 9:20 a 9:50 AM ET en el New York Marriott Marquis. La presentación estará disponible vía webcast y se podrá acceder a ella a través del sitio web de relaciones con inversores de la empresa durante al menos 30 días.
Adagene Inc. (나스닥: ADAG), 항체 기반 치료법에 중점을 둔 생명공학 회사가 Jefferies 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다. 최고전략책임자(Mickael Chane-Du)가 2025년 6월 5일 오전 9시 20분부터 9시 50분(동부시간)까지 뉴욕 매리어트 마퀴스에서 투자자와 일대일 미팅을 진행하고, 파이어사이드 채팅에 참여할 예정입니다. 발표 내용은 웹캐스트를 통해 제공되며 회사 투자자 관계 웹사이트에서 최소 30일간 시청할 수 있습니다.
Adagene Inc. (Nasdaq : ADAG), une société de biotechnologie spécialisée dans les thérapies à base d’anticorps, a annoncé sa participation à la Jefferies Global Healthcare Conference 2025. Le directeur de la stratégie, Mickael Chane-Du, participera à des rendez-vous individuels avec des investisseurs et prendra part à une discussion informelle le 5 juin 2025, de 9h20 à 9h50 ET, au New York Marriott Marquis. La présentation sera disponible en webdiffusion et accessible via le site des relations investisseurs de la société pendant au moins 30 jours.
Adagene Inc. (Nasdaq: ADAG), ein Biotechnologieunternehmen mit Schwerpunkt auf Antikörper-basierten Therapien, gab seine Teilnahme an der Jefferies Global Healthcare Conference 2025 bekannt. Chief Strategy Officer Mickael Chane-Du wird Einzelgespräche mit Investoren führen und am 5. Juni 2025 von 9:20 bis 9:50 Uhr ET im New York Marriott Marquis an einem Fireside Chat teilnehmen. Die Präsentation wird per Webcast verfügbar sein und über die Investor-Relations-Website des Unternehmens mindestens 30 Tage lang abrufbar sein.
- None.
- None.
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place June 3-5 in New York, New York.
Jefferies Global Healthcare Conference 2025
- Fireside Chat Date: Thursday, June 5
- Fireside Chat Time: 9:20-9:50 AM (Eastern Time)
- Location: New York Marriott Marquis
- Webcast: https://wsw.com/webcast/jeff319/adag/1805752
A webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
Adagene
raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com
FAQ
When is Adagene (ADAG) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Adagene (ADAG) at the Jefferies Healthcare Conference 2025?
Where can investors watch Adagene's (ADAG) Jefferies conference presentation?
What type of meetings will Adagene (ADAG) participate in at the Jefferies conference?
